Case Study: Cefuroxime Axetil: An Oral Prodrug of Cefuroxime

Fuchs, Tarra

doi:10.1007/978-0-387-49785-3_37

Cited by 4 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[13] One case example is Ceftin by GSK, an amorphous form of the antibiotic cefuroxime which is completely insoluble in water in its original form. [14] Because the solubility of amorphous forms relies on the reduces molecular-packing stability of the latter, they can be very challenging to form and stabilize. Therefore, they are often protected by multiple patents which prevent early generic entry.…”

Section: Drug Modificationmentioning

confidence: 99%

Review of Commercially Available Nano-Drugs and Nano-Delivery Systems: Challenges and Perspectives

Boudovitch,

Sakaya,

Uzundurukan

et al. 2023

Preprint

View full text Add to dashboard Cite

Nano-drugs and nano-delivery systems are rapidly evolving, with new strategies emerging in the current practices. The evolution of these technologies began with modifying the chemical structure, progressing to supramolecular ionic complexes, and culminating in elegant ad hoc delivery systems. Nanoparticles have numerous benefits as a carrier system for delivering therapeutic agents to intra-arterial sites. These benefits include their subcellular size, targeted surfaces, good suspensibility, and uniform dispersity, making them an ideal choice for catheter-based delivery. Despite the advancements made in the field of nano-drugs and nano-delivery systems, there are still some hurdles to overcome in terms of their commercial availability.The current review presents an updated summary of recent advancements in nano-drugs and nano-delivery systems, including their commercial availability. We aim to discuss the present challenges and prospects of commercially available nano-drugs and nano-delivery systems. Here, we provide a precise and informative overview of the current state of these technologies and underscore the potential they hold for future developments. Further, we have categorized commercially available modifications, name, parent company and their main applications in nano-drugs.

show abstract

Section: Drug Modificationmentioning

confidence: 99%

Review of Commercially Available Nano-Drugs and Nano-Delivery Systems: Challenges and Perspectives

Boudovitch,

Sakaya,

Uzundurukan

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…On oral administration, the bioavailability of the drug is 37% only [3,5], and the absorption of tablet is greater when taken after food i.e. 37% to 52% [6].…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic and Bioequivalence Studies of Oral Cefuroxime Axetil 250 mg Tablets in Healthy Human Subjects

Muhammad¹,

Shoaib²,

Yousuf³

2014

J Bioequiv Availab

View full text Add to dashboard Cite

“…For an ester prodrug, the oral bioavailability could be dramatically changed if taken after food [3][4][5] . In terms of oral administration, the bioavailabil ity of the drug only achieved 37 % [6,7] and the absorption of tablet remarkably elevated from 37 to 52 % after a meal [3] . The pharmacokinetic characteristics such as peak plasma concentration (T max ), peak plasma concentration (C max ) and area under curve (AUC) of cefuroxime axetil have been reported and the bioavailabil ity of cefuroxime axetil could be affected by food [3][4][5][6]8,9] .…”

mentioning

confidence: 99%

Diet-induced Alterations in Pharmacokinetics of Cefuroxime Axetil in Healthy Chinese Subjects

Wang¹,

Fan²,

Cheng³

et al. 2019

ijps

View full text Add to dashboard Cite

Wang et al.: Diet-induced Alterations in Pharmacokinetics of Cefuroxime Axetil This study was conducted to evaluate the pharmacokinetics, safety and gender difference of cefuroxime axetil after single dose administration under fasting and fed conditions in healthy Chinese male and female subjects. In an open-label, two-period study, 26 subjects received a single 250 mg oral dose with or without food. Blood samples were collected at scheduled time points till 24 h after drug administration and cefuroxime axetil concentration in blood was analysed using liquid chromatography with tandem mass spectrometry. Twenty-three subjects completed the study. Under fed state, the median time to peak plasma concentration of cefuroxime axetil was delayed by approximately 0.5 h compared with fasting state (2.23 h vs. 3.01 h) and there was a 43.9 % increase in the total systemic exposure (AUC0-∞) and 8.3, 38.7, 34.1 % reduction in elimination half-life, apparent volume of distribution and apparent clearance, respectively. No significant difference presented in maximum concentration achieved (p>0.05). There was no gender difference in pharmacokinetics and no serious adverse events reported, as well. This study indicated that the extent of absorption of cefuroxime axetil is significantly increased under fed state and it is recommended to be administrated after a meal.

show abstract

Case Study: Cefuroxime Axetil: An Oral Prodrug of Cefuroxime

Cited by 4 publications

References 26 publications

Review of Commercially Available Nano-Drugs and Nano-Delivery Systems: Challenges and Perspectives

Review of Commercially Available Nano-Drugs and Nano-Delivery Systems: Challenges and Perspectives

Pharmacokinetic and Bioequivalence Studies of Oral Cefuroxime Axetil 250 mg Tablets in Healthy Human Subjects

Diet-induced Alterations in Pharmacokinetics of Cefuroxime Axetil in Healthy Chinese Subjects

Contact Info

Product

Resources

About